Objective: To describe the outcome of an unselected large series of patients with lymphoblastic lymphoma (LBL) treated in a single institution.
Introduction
Among the high-grade non-Hodgkin's lymphomas (NHL) [1] , lymphoblastic lymphoma (LBL) is a distinctive disease, with cytological and histological features similar to those of T-acute-lymphoblastic leukemia (ALL) [2, 3] . Its incidence is greatest in adolescents and young adults although many reports of LBL describe patients older than 60 years. Men are more often affected than women. Mediastinal involvement and pleural effusions are frequent at diagnosis. LBL is characterized by a high mitotic rate and rapid proliferation with bone marrow, blood and central nervous system (CNS) involvement during the course of the disease [4, 5] .
Until the end of the 1970s, reports of LBL described a poor outcome with few patients achieving long-term survival [4, 6] . In 1981, a pilot study by Coleman et al. [7] using a multi-agent chemotherapy regimen reported an improved outcome at three years with 61% and 56% actuarial survival and relapse-free survival, respectively. Coleman et al. [8] reported the results of a second study of 44 patients in 1986. The complete response (CR) rate was 95% and the projected three-year freedom from relapse and total survival was 58%. Two prognostic groups were identified on the basis of Ann Arbor stage, lactic dehydrogenase (LDH) level, and CNS and bone marrow involvement. Subsequently, other reports of multi-agent chemotherapy, modeled after treatment for ALL, demonstrated significant improvement in the treatment of LBL with excellent results in the induction of CR and a significant improvement in long-term diseasefree survival (DFS) [9, 10] .
Even with these therapeutic advances, high-risk patients as defined by Coleman [8] have a poor rate of freedom from relapse (19% at five years). New therapeutic approaches such as myeloablative therapy and bone marrow transplantation (BMT) were needed for these patients. Milpied et al. [11] reported the first series of poorprognosis LBL patients who received allogeneic or autologous BMT in first CR (CR1) in 1989. The four-year DFS was 68%, with no difference between patients receiving allogeneic or autologous BMT. Subsequently, improved long-term DFS in patients with poor-prognosis LBL was reported with high-dose chemotherapy followed by BMT [12, 13] . More recently, Morel et al. [14] analyzed 80 adults with LBL to assess predictors of CR rate, CR duration and survival. Advanced age and high LDH values were shown to be the two major adverse factors.
We report the results of our experience in 62 LBL patients from a single institution. Patients first received either chemotherapy regimens as used in intermediate and high-grade NHL or chemotherapy regimens similar to those used in ALL. BMT was then performed in 38 patients. In this retrospective analysis, the treatment results in patients are described and prognostic factors are defined.
Patients and methods

Patients
Sixty-two patients with a diagnosis of LBL were treated between January 1980 and December 1992 in our institution. The histological diagnosis was made using the working formulation. All patients underwent physical examination, bone marrow aspirate and/or biopsy, chest X-ray, CT scan of chest, abdomen and pelvis, lumbar puncture, and cranio-spinal CT scan if the lumbar puncture showed abnormalities. Other examinations were used according to the site of disease for each patient (ultrasonic examinations, endoscopies, biopsies). Stage of disease was defined according to the Ann Arbor classification. Patients with more than 30% of blasts in the marrow or circulating blasts were considered to have lymphoblastic leukemia and were not included in this series.
Treatment
Chemotherapy
Thirty-eight patients received therapy according to ALL protocols: 27 were treated according to French multicenter ALL protocols [16, 17] [21] or LNH 87 [22] protocols. The induction course with both protocols included adriamycin 75 mg/m 2 and cyclosphosphamide 1200 mg/m 2 on day 1, vindesine 2 mg/m 2 and bleomycin 10 mg on days 1 and 5 and prednisolone 60 mg/m 2 on days 1-5 (ACVBP). IT methotrexate was injected once per ACVBP course for CNS prophylaxis. Four courses with a two-week interval were delivered and patients who achieved CR received consolidation chemotherapy for four months with sequential courses of methotrexate, etoposide, ifosfamide. asparaginase and cytosine-arabinoside in the LNH 84. In the LNH 87 protocol, this consolidation chemotherapy was randomized versus autologous BMT.
Four patients received chemotherapy without being included in protocols (two anthracychne-containing regimens and two anthracycline-free regimens). Exclusion criteria were: two referred patients, one with coronary disease and one patient 65 years old with a poor PS.
Bone marrow transplantation
Thirty patients received BMT after achievement of CR to induction treatment. Twelve patients with an HLA-identical sibling underwent allogeneic transplantation and eighteen patients with no identical donor received autologous transplantation. Autologous BMT was performed as a consolidation therapy from 1982 to June 1990 when one of the following features was present at diagnosis: age under 50 years, stage IV. bulky disease. After June 1990, autologous BMT was performed in all patients younger than 55 years with a diagnosis of LBL. Allogeneic transplantation was generally done each time a histocompatible donor was identified. The myeloablative regimen usually consisted of fractioned total body irradiation (10 Gy) and cyclophosphamide 60 mg/kg for two days. This was true for 55% (/; = 11) of the patients with autologous BMT and 77% (n = 10) of those with allogeneic BMT. Autologous marrow was not purged.
Response criteria
Response was evaluated at the end of induction chemotherapy. CR was defined as the disappearance of all clinical, biologic, radiologic and histologic abnormalities previously related to disease. A partial response (PR) indicated a regression of at least 50% of the measurable sites of disease. Failures included all other situations (stable disease, progressive disease, disease-related death).
Statistical analysis X~-test was used to compare CR rates. Overall survival (OS) was calculated from the date of diagnosis, death being scored as an event with censoring of other patients at the time of last follow-up. Event-free survival (EFS) was also calculated from the date of diagnosis, with relapse or death being scored as an event, and with censoring of other patients at the time of last follow-up. To draw survival curves, we used Kaplan and Meier estimates [23] , Curves were compared by the logrank test [24] . Prognostic factors were assessed in a multivariate analysis by the Cox proportional hazard model in a forward stepwise regression [25] . Survival rates and relative risk (RR) are presented with their 95% confidence intervals (95% CI).
Results
Patient characteristics
Clinical characteristics are listed in Table 1 . There is a male predominance with a ratio of 3:1. The mean age was 35 years (range 14-70 years). Thirty-nine patients (63%) were stage IV, usually on the basis of pleural effusion (16 patients) and bone marrow involvement (14 patients). Other extra-nodal sites of disease were: CNS (four patients), liver (four patients), skin (three patients), lung (two patients), bone (two patients), kidney (two patients), gastrointestinal tract, breast, ovary, testis (one patient each). Eleven of these 39 stage IV patients had more than one site of extra-nodal disease. The combination of pleural effusion and bone marrow involvement was especially prominent. Bulky mediastinal mass was present in 63% of patients (70% in stage II, 50% in stage III and 61% in stage IV). Moreover, we analyzed the X" test. b The n total of patients include four patients who received chemotherapy without being included in NHL or ALL protocols (see 'Patients and methods').
impact of two other factors identified in the International Prognostic Factors Project [15] . Performance status (PS), available in 34 patients, was ^ 2 in half of the patients at diagnosis. LDH, measured in 28 patients, was abnormal in 22 patients (78.5%). Pooling these data, we identified a population of 44 patients less than 60 years old for whom at least two factors were known at diagnosis. Of these 44 patients, 21 were low-and lowintermediate risk, and 23 were high-intermediate and high-risk.
Response to induction treatment and survival
Forty-six patients (74%) achieved CR and 16 (26%) failed to achieve CR, with five PR and 11 failures, as shown in Table 2 . With a median follow-up of 93 months (range 36-187), the OS rate for the patients as a whole is 49% at five years (36.5-61.8) and 41% at 10 years (27.8-54.8). The five-and 10-year EFS rates are, respectively, 45% (32.4-58.1) and 37% (24.0-50.8, Figure l) .Of the 16 patients who failed to achieve CR to induction treatment, thirteen received salvage treatment (chemotherapy eight; autologous BMT four; allogeneic BMT one). To date, only one patient in this group is still alive without disease, with a follow-up of 93 months: he received allogeneic grafting upon failure at the seventh month after diagnosis. The 15 remaining patients died of lymphoma at a median time of 11 months following induction therapy (range 1-28).
BMT as a consolidation to CR
Thirty-eigth patients received BMT in our series. The five-and 10-year OS rates are 60% (45.0-76.1) and 56% (40.1-72.9) (Figure 2 ), while EFS is, respectively, 58% (42.2-73.6) and 54% (37.2-70.3). The characteristics of 30 patients who underwent BMT after achieving CR are listed in Table 3 . Eighteen patients received autologous BMT. Sixteen were in first CR (CR1) and two in second CR (CR2). The median time between diagnosis and autologous BMT was six months (four to 14). With a median follow-up of 85 months (range 36-156), 11 patients are alive in continuous CR (10 CR1 + one CR2). To date, six patients have died of recurrent lymphoma a median of 13 months (seven to 21 months) after BMT and one died at 70 months of Table 3 . BMT as consolidation to complete responders: Characteristics and follow-up of patients.
Auto BMT Table 4 . Overall survival and event-free survival in high-risk patients transplanted or not according to the two prognostic factor systems (Coleman, International index [8, 15] Acquired Immunodeficiency Syndrome (AIDS) while in continuous CR. Twelve patients received allogeneic BMT. Eleven allografts were in CR1, one was in CR2. With a median follow-up of 114 months (range 41-168), 10 patients, all of whom were allografted in CR1, are alive and well. Two patients died five and eight months post-transplant of acute graft-ver?w.s-host disease (GVHD) and graft rejection.
Of the 30 patients who were transplanted in CR, 21 were in the high-risk group as defined by Coleman, and 15 were high-risk as defined in the International Prognostic Factors Project. The five-year OS are, respectively, 66% (49.0-84.3) and 80% (59.7-100.0), compared to the 33% (2.5-64.1) and 28% (0.0-62.0) in the non-transplanted patient group (Table 4) .
Induction CRs who received no transplants
Thirteen patients in CR1 did not undergo transplantation for the following reasons: age more than 50 years (four cases), patient refusal (one case), diagnosis prior to 1982 (five cases), unknown (three cases). The median age of these 13 patients was 48 years (range 14-65). Seven patients had stages II or III disease, while six had stage IV. The ALL regimen was delivered to five patients, NHL chemotherapy to seven patients and one patient was given no anthracycline-based chemotherapy due to advanced age and poor cardiac function. The median 
Prognostic factors
Univariate analysis Age (Median age was the chosen cut-off value), sex, mediastinal involvement, bone marrow involvement, CNS involvement, BMT procedure, and source of BMT (autologous, allogeneic) were analyzed in order to determine whether they had an effect on overall survival and event-free survival. There was no significant statistical difference in OS and EFS for age, sex, mediastinal involvement, BM involvement, or CNS involvement. The most significant factor in prolonged OS (/>,) and EFS (P2) was BMT as consolidation to induction treatment (Pi = 0.005, P 2 -0.004; Figure 2 
Multivariate analysis
Only BMT as consolidation to induction CR remained independently associated with survival (P = 0.008, 1.2-4.8) and EFS (/>= 0.007, 1.2-4.6).
Discussion
The aim of this retrospective study was to describe the outcome of an unselected large series of patients with LBL from diagnosis to death or other event. Of the 62 patients, 25 are long-term disease-free survivors. In this discussion, we will compare these results with those reported in the adult LBL literature. The characteristics of our population are similar to those in previous reports: the majority of patients were under 40 years, most were male, mediastinal involvement at diagnosis was commun, and there was a high incidence of extra-nodal disease [8, 14, 26] .
The treatments used in our our series to induce CR were usually reported in adult LBL literature as successful therapeutic modalities [21, 22, 27, 28] . Our CR rate was 74%. Of the eleven patients who failed to achieve CR or PR, nine received NHL-like regimens rather than ALL induction chemotherapy. In his report, Morel [14] found 14 non-responding patients, 11 received NHL induction chemotherapy. These results are similar to ours, but we found a significant difference in CR rate between the two treatments groups (P -0.01) in contrast to Morel. Nevertheless, he found a trend to a lower CR rate in the CHOP group. Liang et al. [29] treated 20 LBL adult patients with NHL-like regimens, such as m-BACOD [27, 28] or BACOP [30] , and they observed 50% of non-responders.
All of these results demonstrate that initial conventional chemotherapy is not sufficient in LBL and that we need more intensive chemotherapy to improve CR rate, similar to those used in ALL or those used in the LNH 84 or LNH 87 regimens. The patients who received an ALL induction treatment had an 89% CR rate. None of the four patients treated with the LNH 84 or 87 in our study failed to respond. Finally, our results in CR rates compare favorably with those reported by other authors, whose CR rates ranged from 73% to 95% [8] [9] [10] 14, 26] .
The reports of Stanford [8] and the Memorial SloanKettering Cancer Center [10] first demonstrated the role of such intensive chemotherapeutic regimens in achievement of long-term survival, with a five-year OS at 63%. However, both studies reported a poor outcome of patients with unfavorable prognostic factors. Slater described a high-risk group of patients older than 30 years with high CBC counts and failure or delay in CR. The five-year survival for this group ranged between 19% and 40%. Coleman also identified a high-risk group defined by CNS or bone marrow involvement or high LDH level with a 19% freedom from relapse rate at five years.
Regardless of these results, some authors reported a role for BMT in long-term survival in patients with aggressive intermediate-and high-grade NHL, including LBL [31, 32] . The first large series of BMT in adult LBL was reported in 1989 by Milpied [11] . Of the 25 reported patients, 21 were high-risk as defined by Coleman. The patients were grafted in CR1 at a median of three months following the CR. The four-year DFS rate reported was 68% with no significant difference between allogeneic (12 patients) and autologous (13 patients) transplantation. In 1991, the European BMT registry reported 47 patients with LBL and bone marrow or CNS involvement at diagnosis [12] , who underwent BMT after completing CR. The reported DFS was 46% with a median follow-up of 30 months. The relapse rate was 44% for autologous BMT and 22% for allogenic BMT.
Four recent reports describe attempts to investigate the impact of autologous BMT for adult high-risk LBL in remission. Santini et al. [33] reported a series of 40 patients who received an intensive chemotherapy induction. The twenty-one patients eligible for autologous BMT in CR1 were poor-risk with advanced stage and a high degree of bone marrow involvement. Fourteen patients were alive and well five to 72 months post-BMT with a DFS probability of 66%. Baro et al. [34] published a retrospective study in 22 adult patients who were treated with high-dose chemotherapy and autologous BMT. The two-year OS and DFS for patients transplanted in either CR1 or some other disease status (i.e., later CR, PR, sentive relapses) were not significantly different (85% vs. 73%, 77% vs. 50%). However, of the 14 patients autografted in CR1, eight were in the highrisk group and all were DFS eight to 92 months after BMT. Verdonck et al. [35] reported nine poor-risk LBL with high-level LDH and CS IV in all the patients. The autologous BMT was performed in CR1 within two months after the last chemotherapeutic course. Six patients were in unmaintained first remission with a median follow-up duration of 53 months (range 12-113) after transplantation. The largest series published in autologous BMT in LBL was reported by the EBMT group [36] . The study was a retrospective analysis of 214 patients who underwent autologous BMT at different stages of disease. While the actuarial OS rate at six years was 42% for the group as a whole, it was, respectively, 63%, 31% and 15% when BMT was performed in CR1, CR2 or in resistant disease. Moreover, the five-year actuarial OS rate for poor-risk patients is 48%), compared with the 19% rate in the series reported by Coleman [8] . In our series, the BMT procedure was the most significant prognostic factor in both univariate and multivariate analyses. The poor long-term survival we found in highrisk patients who do not undergo transplantation after CR accords with Coleman's report.
The source of marrow (allogeneic or autologous) remains questionnable. No randomized studies were conducted in recent years, and the number of patients in the published literature is too low to serve as a basis for conclusions. A case-controlled study reported by the BMT group [37] to compare allogeneic and autologous BMT in NHL attempts to tackle this question. Of the 98 transplanted LBL patients (49 allogeneic + 49 autologous), a greater relapse rate is observed in autotransplanted patients (48% vs. 24% in allogeneic). However, the actuarial progession-free survival was not different (57% in allogeneic vs. 44% in autologous), probably due to a higher procedure-related mortality in the allogeneic group (24% vs. 10% in autologous). In addition, this report suggests a graft versus lymphoma effect for the allogeneic procedure, as a significantly lower relapse or progression rate was observed in patients who developed chronic GVHD. The low frequency of LBL in adults and the probability of having an HLA-identical sibling could explain the fact that more data are needed on experience in allogeneic BMT in LBL.
In this study, we found two key factors in OS and EFS in adult LBL. They are bone marrow transplant after achievement of CR, and allogeneic transplantation. The International Prognostic Index does not seem applicable to adult LBL when tested in our series, but prognostic factors such as PS or LDH value were not available for all patients. This may make application of the International Prognostic Index difficult. Our results suggest that LBL in adults is an aggressive disease in which more is better. Induction treatment to achieve CR must be similar to induction treatment in ALL, and this concept is consistent with other reported results. If maintenance chemotherapy may cure some patients, transplant treatment is a major alternative approach in high-risk patients or in a salvage strategy. In such situations, allogeneic transplantation must be considered whenever a histocompatible donor is identified. Indeed, LBL is not a common disease in adults, and it could be many years before multicentric studies comparing conventional chemotherapy, autologous, or allogeneic transplantation provide definitive recommendations for the treatment of adult LBL.
